Sebastian C J Steiniger
Overview
Explore the profile of Sebastian C J Steiniger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
340
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Steiniger S, Glanville J, Harris D, Wilson T, Ippolito G, Dunham S
Biologicals
. 2017 Jan;
46:81-87.
PMID: 28131552
Next-Generation Sequencing combined with bioinformatics is a powerful tool for analyzing the large number of DNA sequences present in the expressed antibody repertoire and these data sets can be used...
2.
Steiniger S, Dunkle W, Bammert G, Wilson T, Krishnan A, Dunham S, et al.
Mol Immunol
. 2014 Feb;
59(1):71-8.
PMID: 24509215
Complementarity determining regions (CDR) are responsible for binding antigen and provide substantial diversity to the antibody repertoire, with VH CDR3 of the immunoglobulin variable heavy (VH) domain playing a dominant...
3.
Staflin K, Krueger J, Hachmann J, Forsyth J, Lorger M, Steiniger S, et al.
Clin Exp Metastasis
. 2010 Mar;
27(4):217-31.
PMID: 20225083
Advanced metastatic disease is difficult to manage and specific therapeutic targets are rare. We showed earlier that metastatic breast cancer cells use the activated conformer of adhesion receptor integrin alphavbeta3...
4.
Fukuchi K, Steiniger S, Deryugina E, Liu Y, Lowery C, Gloeckner C, et al.
Mol Pharm
. 2009 Nov;
7(1):245-53.
PMID: 19916495
Despite significant progress and notable successes in tumor therapy, malignant disease remains an extremely difficult problem in today's health care setting. There is, however, an increasing application of new therapies...
5.
Steiniger S, Coppinger J, Kruger J, Yates 3rd J, Janda K
Stem Cells
. 2008 Sep;
26(12):3037-46.
PMID: 18802034
A multifaceted approach is presented as a general strategy to identify new drug targets in a breast cancer stem cell-containing side population. The approach we have utilized combines side population...
6.
Yoneda Y, Steiniger S, capkova K, Mee J, Liu Y, Kaufmann G, et al.
Bioorg Med Chem Lett
. 2008 Feb;
18(5):1632-6.
PMID: 18243696
Tumor targeting peptides are promising vehicles for site-directed cancer therapy. Pep42, a cyclic 13-mer oligopeptide that specifically binds to glucose-regulated protein 78 (GRP78) and internalized into cancer cells, represents an...
7.
Liu Y, Steiniger S, Kim Y, Kaufmann G, Felding-Habermann B, Janda K
Mol Pharm
. 2007 Mar;
4(3):435-47.
PMID: 17373820
Major obstacles in the development of new therapeutic anticancer drugs are the low bioavailability of hydrophilic substances and the nonspecific toxicity toward healthy tissues. As such, cell-targeting oligopeptides have emerged...
8.
Steiniger S, Altobell 3rd L, Zhou B, Janda K
Mol Immunol
. 2007 Jan;
44(10):2749-55.
PMID: 17210180
The protective antigen (PA(83)) of Bacillus anthracis is the dominant antigen in natural and vaccine-induced immunity to anthrax infection. Three human single-chain variable fragments (scFvs) against cell bound PA were...
9.
Kim Y, Lillo A, Steiniger S, Liu Y, Ballatore C, Anichini A, et al.
Biochemistry
. 2006 Aug;
45(31):9434-44.
PMID: 16878978
Peptidic ligands can be used for specific cell targeting and the delivery of payloads into the target cell. Here we describe the screening of a pool of cyclic peptide phage...
10.
Junghans M, Loitsch S, Steiniger S, Kreuter J, Zimmer A
Eur J Pharm Biopharm
. 2005 Jun;
60(2):287-94.
PMID: 15939239
In the present study, cationic lipid-peptide-DNA-complexes (LPDs) consisting of AH-Chol-liposomes and protamine-phosphodiester-oligonucleotide-particles (proticles) were introduced as carriers for antisense therapy. The LPDs were physically characterized, and a possible mechanism for...